Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026

Rhea-AI Summary

Dyadic (Nasdaq: DYAI) plans to report its Q2 2026 financial results and host a corporate update conference call on Wednesday, August 12, 2026, at 5:00 p.m. Eastern Time. Investors can join via toll-free and international dial-in numbers or a live webcast, with a replay available on Dyadic's investor relations website.

Market Context

The tagged history records two prior scheduling notices with an average move of -0.52%, adding a mix...

Analysis

The tagged history records two prior scheduling notices with an average move of -0.52%, adding a mixed historical benchmark to this date announcement. Recent insider net selling is a risk; watch the reported quarter and management update.

Key Figures

Quarter-end date: June 30, 2026 Conference call date: August 12, 2026 Conference call time: 5:00 p.m. Eastern Time

3 metrics

Quarter-end date June 30, 2026 Quarter for which financial results will be reported

Conference call date August 12, 2026 Corporate update conference call

Conference call time 5:00 p.m. Eastern Time August 12, 2026 conference call

Previous Conferences,earnings date Reports

2 past events · Latest: Apr 29 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 29	Earnings date notice	Neutral	+3.5%	Announced Q1 2026 results date and conference call details
Mar 11	Earnings date notice	Neutral	-4.6%	Announced full-year 2025 results date and conference call details

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The two prior tag-matched earnings-date announcements produced mixed 24-hour reactions, averaging -0.52%.

Key Terms

gene expression

1 terms

gene expression technical

"utilizing its proprietary gene expression platforms"

Gene expression is the process by which a cell reads a gene’s instructions and produces the molecules—usually proteins—that do work in the body, like building structures or sending signals. Think of a gene as a recipe and expression as the act of cooking: whether and how much a dish gets made affects the final product. Investors care because changes in gene expression underlie diseases, treatment responses, biomarkers and drug targets, so they can influence clinical outcomes, regulatory decisions and commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JUPITER, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the quarter ended Jun 30, 2026 and host a corporate update conference call on Wednesday, August 12, 2026.

Conference Call Information
Date: Wednesday, August 12, 2026
Time: 5:00 p.m. Eastern Time
Dial-in numbers: Toll Free: +1-877-407-9219 / +1 412-652-1274
Conference ID: 13761129

Webcast Link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=b9s8dhjS An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.

If you have any questions that you would like to ask management during the Q&A session, please email jlavalley@dyadic.com prior to the conference call.

About Dyadic Applied BioSolutions

Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic's C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information, please visit www.dyadic.com.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at www.dyadic.com.

Contact:
Ping Rawson
Dyadic Applied BioSolutions
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com 

FAQ

When will Dyadic (Nasdaq: DYAI) report its Q2 2026 financial results?

Dyadic will report its Q2 2026 financial results on Wednesday, August 12, 2026. According to Dyadic, the results will be discussed during a corporate update conference call held the same day at 5:00 p.m. Eastern Time.

What time is Dyadic’s Q2 2026 earnings conference call on August 12, 2026?

Dyadic’s Q2 2026 conference call is scheduled for 5:00 p.m. Eastern Time on August 12, 2026. According to Dyadic, the call will include financial results and a corporate update for investors and analysts.

How can investors join the Dyadic (DYAI) Q2 2026 earnings call by phone?

Investors can join by dialing toll-free +1-877-407-9219 or international +1 412-652-1274. According to Dyadic, callers should use Conference ID 13761129 to access the Q2 2026 financial results conference call.

Is there a webcast for the Dyadic Q2 2026 financial results call?

Yes, Dyadic will provide a live webcast for the Q2 2026 call at the supplied Chorus Call link. According to Dyadic, an archived replay will be available within 24 hours on the investor relations section of www.dyadic.com.

How can shareholders access the replay of Dyadic’s August 12, 2026 earnings webcast?

Shareholders can access the replay by using the same webcast link provided for the live event. According to Dyadic, the replay archive will be available within 24 hours on the company’s investor relations webpage.

How can investors submit questions for Dyadic’s Q2 2026 earnings call Q&A session?

Investors can email questions to jlavalley@dyadic.com before the conference call. According to Dyadic, submitted questions may be addressed by management during the Q&A portion of the August 12, 2026 corporate update call.